Inventiva SA
PAR:IVA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.45
4.24
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IVA stock under the Base Case scenario is 5.63 EUR. Compared to the current market price of 2.45 EUR, Inventiva SA is Undervalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Inventiva SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IVA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Inventiva SA
Balance Sheet Decomposition
Inventiva SA
Current Assets | 48.2m |
Cash & Short-Term Investments | 26.9m |
Receivables | 16.2m |
Other Current Assets | 5.1m |
Non-Current Assets | 21.4m |
PP&E | 9.1m |
Intangibles | 541k |
Other Non-Current Assets | 11.7m |
Current Liabilities | 50.2m |
Accounts Payable | 37.7m |
Accrued Liabilities | 3.6m |
Other Current Liabilities | 8.9m |
Non-Current Liabilities | 51.4m |
Long-Term Debt | 32.2m |
Other Non-Current Liabilities | 19.3m |
Earnings Waterfall
Inventiva SA
Revenue
|
15.6m
EUR
|
Operating Expenses
|
-115.6m
EUR
|
Operating Income
|
-100m
EUR
|
Other Expenses
|
-4.2m
EUR
|
Net Income
|
-104.2m
EUR
|
Free Cash Flow Analysis
Inventiva SA
EUR | |
Free Cash Flow | EUR |
IVA Profitability Score
Profitability Due Diligence
Inventiva SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Inventiva SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
IVA Solvency Score
Solvency Due Diligence
Inventiva SA's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Inventiva SA's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IVA Price Targets Summary
Inventiva SA
According to Wall Street analysts, the average 1-year price target for IVA is 13.11 EUR with a low forecast of 6.06 EUR and a high forecast of 21 EUR.
Dividends
Current shareholder yield for IVA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
IVA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Contact
IPO
Employees
Officers
The intrinsic value of one IVA stock under the Base Case scenario is 5.63 EUR.
Compared to the current market price of 2.45 EUR, Inventiva SA is Undervalued by 56%.